PMID- 14713399
OWN - NLM
STAT- MEDLINE
DCOM- 20040426
LR  - 20220317
IS  - 1523-3774 (Print)
IS  - 1523-3774 (Linking)
VI  - 6
IP  - 1
DP  - 2004 Feb
TI  - Outcome measures in osteoarthritis: randomized controlled trials.
PG  - 20-30
AB  - Accepted outcome measures in randomized controlled trials (RCTs) in 
      osteoarthritis (OA) include patient-reported assessments of physical function and 
      health-related quality of life (HRQOL). Available data can inform treatment 
      decisions when statistically significant changes are viewed in terms of 
      clinically important improvements. Patient-reported outcomes validated in OA 
      include global assessments of pain, disease activity, and disease-specific and 
      generic measures of physical function and HRQOL. Definitions of minimum 
      clinically important differences (MCID) have been derived from RCTs with physical 
      therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 
      selective agents. Definitions of MCID should serve only as guidelines based on 
      mean changes in a treatment group, and do not necessarily reflect clinically 
      meaningful improvements for an individual patient. They help to interpret data 
      across treatments and patient populations. Definitions of MCID may differ for the 
      type of intervention assessed; additional methodologic issues must be addressed 
      when evaluating nonpharmacologic treatments. Based on RCTs in OA evaluating 
      physical therapy, cyclooxygenase-2 agents, and NSAIDs, the Western Ontario and 
      McMaster Osteoarthritis Index is valid, reliable, sensitive to change, and 
      correlates closely with the generic Medical Outcomes Survey Short-Form 36 measure 
      of HRQOL. When evaluating RCT data, understanding derivation and MCID values of 
      outcome measures facilitates informed therapeutic decisions regarding therapeutic 
      interventions.
FAU - Strand, Vibeke
AU  - Strand V
AD  - Division of Immunology and Rheumatology, Stanford University, 306 Ramona Road, 
      Portola Valley, CA 94028, USA. vstrand@aol.com
FAU - Kelman, Ariella
AU  - Kelman A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - N08U5BOQ1K (Glucosamine)
SB  - IM
MH  - Acupuncture
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Disability Evaluation
MH  - Glucosamine/therapeutic use
MH  - Humans
MH  - Low Back Pain/etiology/physiopathology
MH  - Osteoarthritis/complications/drug therapy/physiopathology/*therapy
MH  - Outcome Assessment, Health Care
MH  - Pain Measurement
MH  - *Quality of Health Care
MH  - Randomized Controlled Trials as Topic
RF  - 89
EDAT- 2004/01/10 05:00
MHDA- 2004/04/27 05:00
CRDT- 2004/01/10 05:00
PHST- 2004/01/10 05:00 [pubmed]
PHST- 2004/04/27 05:00 [medline]
PHST- 2004/01/10 05:00 [entrez]
AID - 10.1007/s11926-004-0080-6 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2004 Feb;6(1):20-30. doi: 10.1007/s11926-004-0080-6.